Boysen Bio ApS: Financial statements 2019
CVR: 38655590
Source: annual report 2019, Danish Business Authority
01/07/2018 – 30/06/2019
Boysen Bio ApS (CVR 38655590) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK -8,610 and a net result of DKK -17,696. Equity in the 2019 report amounted to DKK 28,977. The solvency ratio was 5.8%.
- Gross Profit
- DKK -8,610
- Profit/Loss
- DKK -17,696
- Equity
- DKK 28,977
- Total Assets
- DKK 498,083
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Boysen Bio ApS
Boysen Bio ApS is a Danish company of the type Anpartsselskab based in Odense SØ, founded in 2017. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named Boysen Bio IVS and GlyProVac IVS. The management consists of Anders Boysen. The company is owned by Anders Boysen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,142 and a net result of DKK -4,142 compared with DKK -4,968 the year before. Equity in the 2025 report amounted to DKK 42,055.